Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab.
AIHA/drug-induced IHA
immunohematology (RBC serology, blood groups)
transfusion complications-non-infectious
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
25
04
2022
received:
03
03
2022
accepted:
29
04
2022
pubmed:
20
5
2022
medline:
14
7
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
Hyperhemolysis syndrome (HHS) is a severe delayed hemolytic transfusion reaction seen in sickle cell disease (SCD) patients, characterized by destruction of donor and recipient RBCs. It results in a drop in hemoglobin to below pretransfusion levels and frequently reticulocytopenia. We report a case of a man in his thirties with SCD with a recent hospitalization 2 weeks prior for COVID-19. His red cell antibody history included anti-Fy(a) and warm autoantibody. At that time, he was given 2 units of RBC and discharged with a hemoglobin of 10.2 g/dl. He returned to the hospital approximately 1.5 weeks later with hemoglobin 6.0 g/dl and symptoms concerning for acute chest syndrome. Pretransfusion testing now showed 4+ pan-agglutinin in both gel-based and tube-based testing. Alloadsorption identified an anti-N and a strong cold agglutinin. Three least incompatible units were transfused to this patient over several days, with evidence of hemolysis. Further reference lab work revealed anti-Fy We present a case of HHS proximate to recent SARS-CoV-2 infection with multiple allo and autoantibodies identified. Information on the relationship between SARS-CoV-2 infection and HHS is limited; however, it is possible that inflammation related to COVID-19 could predispose to HHS. Tocilizumab is an approved treatment for COVID-19. Additionally, tocilizumab appears to be a promising treatment option for patients with HHS.
Sections du résumé
BACKGROUND
Hyperhemolysis syndrome (HHS) is a severe delayed hemolytic transfusion reaction seen in sickle cell disease (SCD) patients, characterized by destruction of donor and recipient RBCs. It results in a drop in hemoglobin to below pretransfusion levels and frequently reticulocytopenia.
CASE REPORT
We report a case of a man in his thirties with SCD with a recent hospitalization 2 weeks prior for COVID-19. His red cell antibody history included anti-Fy(a) and warm autoantibody. At that time, he was given 2 units of RBC and discharged with a hemoglobin of 10.2 g/dl. He returned to the hospital approximately 1.5 weeks later with hemoglobin 6.0 g/dl and symptoms concerning for acute chest syndrome. Pretransfusion testing now showed 4+ pan-agglutinin in both gel-based and tube-based testing. Alloadsorption identified an anti-N and a strong cold agglutinin. Three least incompatible units were transfused to this patient over several days, with evidence of hemolysis. Further reference lab work revealed anti-Fy
DISCUSSION
We present a case of HHS proximate to recent SARS-CoV-2 infection with multiple allo and autoantibodies identified. Information on the relationship between SARS-CoV-2 infection and HHS is limited; however, it is possible that inflammation related to COVID-19 could predispose to HHS. Tocilizumab is an approved treatment for COVID-19. Additionally, tocilizumab appears to be a promising treatment option for patients with HHS.
Identifiants
pubmed: 35588309
doi: 10.1111/trf.16932
pmc: PMC9347625
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Hemoglobins
0
Isoantibodies
0
tocilizumab
I031V2H011
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1446-1451Informations de copyright
© 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Am J Hematol. 2020 Aug;95(8):E192-E194
pubmed: 32358817
Immunohematology. 2005;21(2):48-52
pubmed: 15981343
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Am J Hematol. 2010 Jan;85(1):91-2
pubmed: 20029943
Transfus Med Rev. 2010 Jan;24(1):64-7
pubmed: 19962576
Blood Adv. 2020 Jan 28;4(2):327-355
pubmed: 31985807
Case Rep Med. 2016;2016:5656320
pubmed: 27688774
Emerg Infect Dis. 2020 Oct;26(10):2473-2476
pubmed: 32639228
Transfusion. 2015 Oct;55(10):2398-403
pubmed: 25989361
Br J Haematol. 2019 Sep;186(6):e212-e214
pubmed: 31368112
Am J Hematol. 2020 Jul;95(7):876-878
pubmed: 32282956
Br J Haematol. 2020 Jul;190(1):31-32
pubmed: 32369626
Sci Rep. 2021 Oct 5;11(1):19728
pubmed: 34611251
Eur J Hosp Pharm. 2021 Feb 24;:
pubmed: 33627476
Cureus. 2021 Dec 12;13(12):e20356
pubmed: 35028233
Transfusion. 2019 Oct;59(10):3129-3139
pubmed: 31292968
Transfusion. 2022 Jul;62(7):1446-1451
pubmed: 35588309
Transfusion. 1997 Apr;37(4):376-81
pubmed: 9111274
Transfusion. 2018 Aug;58(8):1965-1972
pubmed: 30198607
Transfusion. 2020 Jan;60(1):30-35
pubmed: 31642065
JAMA Intern Med. 2021 Sep 1;181(9):1241-1243
pubmed: 34028504
Blood Rev. 2022 May;53:100911
pubmed: 34838342
Am J Clin Pathol. 2022 Jun 7;157(6):844-851
pubmed: 34919640
Blood. 2020 Aug 6;136(6):766-768
pubmed: 32559762
Pediatr Blood Cancer. 2022 Feb;69(2):e29330
pubmed: 34490986
Br J Haematol. 2020 Jul;190(2):e92-e93
pubmed: 32453861
Br J Haematol. 2020 Jul;190(1):29-31
pubmed: 32374906
Transfusion. 2022 Mar;62(3):546-550
pubmed: 35092617
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066
J Clin Apher. 2020 Aug;35(4):378-381
pubmed: 32629539
J Investig Med. 2022 Jan;70(1):55-60
pubmed: 34561232
Haematologica. 2020 Aug 13;106(1):310-312
pubmed: 32817291